Focused On-demand Library for Prolyl endopeptidase

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
P48147

UPID:
PPCE_HUMAN

ALTERNATIVE NAMES:
Post-proline cleaving enzyme

ALTERNATIVE UPACC:
P48147; Q8N6D4

BACKGROUND:
The enzyme Prolyl endopeptidase, known for its alternative name Post-proline cleaving enzyme, is distinguished by its ability to cleave peptide bonds adjacent to prolyl residues. This activity is crucial for the degradation of peptides up to 30 amino acids long, underscoring its importance in protein metabolism and cellular regulation.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionality of Prolyl endopeptidase unveils potential pathways for therapeutic intervention. Given its selective peptide cleavage, leveraging this enzyme's activity could lead to novel treatments, particularly in disorders where peptide processing is implicated.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.